Gene: EDEM2

55741
C20orf31|C20orf49|bA4204.1
ER degradation enhancing alpha-mannosidase like protein 2
protein-coding
20q11.22
Ensembl:ENSG00000088298 MIM:610302 Vega:OTTHUMG00000032322 UniprotKB:Q9BV94
NC_000020.11
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
9.673e-1 (AD)  9.404e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs1415771chr20:35146690 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TINF20.819
TRAFD10.799
TXNDC50.797
PHC20.795
ADPGK0.795
LPCAT30.794
WDR10.794
EIF4A10.794
TMEM430.792
KDELR20.79

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.499
OR4F29-0.469
DIO2-0.165
MTRNR2L6-0.162
PRAMEF8-0.162
PRDM14-0.149
OR2T10-0.145
SSX5-0.143
PRAMEF17-0.137
HES5-0.134

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of EDEM2 mRNA"19114083
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of EDEM2 mRNA19770486
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of EDEM2 mRNA21298039
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of EDEM2 mRNA24449571
C006780bisphenol Abisphenol A affects the expression of EDEM2 mRNA21786754
C006780bisphenol A[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM2 mRNA28628672
C006780bisphenol Abisphenol A results in increased expression of EDEM2 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA28628672
D002994ClofibrateClofibrate results in decreased expression of EDEM2 mRNA17585979
C018021cobaltous chloridecobaltous chloride results in decreased expression of EDEM2 mRNA24386269
D003471CuprizoneCuprizone results in increased expression of EDEM2 mRNA26577399
D016572CyclosporineCyclosporine results in increased expression of EDEM2 mRNA20106945|2556210
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA28628672
D005897GlafenineGlafenine results in increased expression of EDEM2 mRNA24136188
C492448ICG 001ICG 001 results in increased expression of EDEM2 mRNA26191083
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of EDEM2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of EDEM2 mRNA28628672
C544151jinfukangjinfukang results in increased expression of EDEM2 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in increased expression of EDEM2 mRNA24796395
D048628KetolidesKetolides analog results in increased expression of EDEM2 mRNA24967691
C012655nimesulidenimesulide results in increased expression of EDEM2 mRNA24136188
D010433PentylenetetrazolePentylenetetrazole affects the expression of EDEM2 mRNA21503142
C006253pirinixic acidpirinixic acid results in decreased expression of EDEM2 mRNA23811191
D010936Plant ExtractsPlant Extracts results in increased expression of EDEM2 mRNA23557933
D012402RotenoneRotenone results in decreased expression of EDEM2 mRNA23186747
D012999SomanSoman results in increased expression of EDEM2 mRNA19281266
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EDEM2 mRNA21570461
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of EDEM2 mRNA22298810
D014415TunicamycinTunicamycin results in increased expression of EDEM2 mRNA22378314
D014635Valproic AcidValproic Acid results in increased expression of EDEM2 mRNA19101580|2317975
C025643vinclozolinvinclozolin results in decreased expression of EDEM2 mRNA23034163
D024483Vitamin K 3EDEM2 affects the susceptibility to Vitamin K 322715409

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004571mannosyl-oligosaccharide 1,2-alpha-mannosidase activityNOTIDA15537790  
GO:0004571mannosyl-oligosaccharide 1,2-alpha-mannosidase activity-IMP25092655  
GO:0004571mannosyl-oligosaccharide 1,2-alpha-mannosidase activity-TAS-  
GO:0005509calcium ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0036509trimming of terminal mannose on B branch-IMP25092655  
GO:0036509trimming of terminal mannose on B branch-TAS-  
GO:0036510trimming of terminal mannose on C branch-TAS-  
GO:0036511trimming of first mannose on A branch-TAS-  
GO:0036512trimming of second mannose on A branch-TAS-  
GO:0097466ubiquitin-dependent glycoprotein ERAD pathway-IMP15537790  
GO:1904154positive regulation of retrograde protein transport, ER to cytosol-IGI24200403  
GO:1904154positive regulation of retrograde protein transport, ER to cytosol-IMP24200403  
GO:1904382mannose trimming involved in glycoprotein ERAD pathway-IMP25092655  
GO ID GO Term Qualifier Evidence PubMed
GO:0005783endoplasmic reticulum-IDA15537790  24200403  
GO:0005788endoplasmic reticulum lumen-IEA-  
GO:0016020membrane-IEA-  
GO:0044322endoplasmic reticulum quality control compartment-TAS-  
KEGG ID KEGG Term
hsa04141Protein processing in endoplasmic reticulum
Reactome ID Reactome Term Evidence
R-HSA-392499Metabolism of proteinsTAS
R-HSA-446203Asparagine N-linked glycosylationTAS
R-HSA-532668N-glycan trimming in the ER and Calnexin/Calreticulin cycleTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-901032ER Quality Control Compartment (ERQC)TAS
R-HSA-901042Calnexin/calreticulin cycleTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal